{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "bd414ff4-9ffb-4ef5-a5ec-fbdbc689435d",
   "metadata": {},
   "source": [
    "## Snippets: Usage of filters and metadata \n",
    "https://cloud.google.com/retail/docs/filter-and-order\n",
    "The expressions for \"filter\" are expected to work in these examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d5683520-b713-4195-a552-0de3a7aa41d1",
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install google.colab"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d4a2107e-890c-4ab2-8dec-d8f5d84f0f32",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from google.colab import auth\n",
    "\n",
    "from google.auth import default\n",
    "auth.authenticate_user()\n",
    "\n",
    "creds, _ = default()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7606566c-19c0-499c-a9c4-ce5e6cedf75c",
   "metadata": {},
   "outputs": [],
   "source": [
    "print(creds)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "67e46dd3-fb9c-471d-ad09-e5d7e620714a",
   "metadata": {},
   "source": [
    "Metadata for the this store <ES_STORE_ID> looks like this:\n",
    "\n",
    "\"id\": \"1\", \"structData\": {\"title\": \"Document1\", \"category\": [\"PersonaA\"], \"name\": \"Document1\"}, \"content\": {\"mimeType\": \"application/pdf\", \"uri\": \"gs://<BUCKETNAME>/data/Document1\"}}\n",
    "\n",
    "\n",
    "{\"id\": \"2\", \"structData\": {\"title\": \"Document2\", \"category\": [\"PersonaA\", \"PersonaB\"], \"name\": \"Document2\"}, \"content\": {\"mimeType\": \"application/pdf\", \"uri\": \"gs://<BUCKETNAME>/data/Document2\"}}\n",
    "\n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c828d9dd-ceec-459c-adf2-8a9d2dbbc138",
   "metadata": {},
   "source": [
    "### Below the filter name: ANY(..) matches ensure the query is against only the documents' metadata satisfying that criteria."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "aab7d70c-c994-42e6-9ef8-9220007d0fa4",
   "metadata": {},
   "outputs": [],
   "source": [
    "%%bash\n",
    "curl -X POST -H \"Authorization: Bearer $(gcloud auth print-access-token)\" \\\n",
    "-H \"Content-Type: application/json\" \\\n",
    "\"https://discoveryengine.googleapis.com/v1beta/projects/<PROJECT>/locations/global/collections/default_collection/dataStores/<ES_STORE_ID>/servingConfigs/default_search:search\" \\\n",
    "-d '{\n",
    "\"servingConfig\": \"projects/<PROJECT>/locations/global/collections/default_collection/dataStores/<ES_STORE_ID>/servingConfigs/default_search\",\n",
    "\"query\": \"claim\",\n",
    "\"filter\": \"name: ANY(\\\"Document1\\\")\"\n",
    "}'"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "21d05f61-eb79-4d9a-ad54-60bc7809e9ee",
   "metadata": {},
   "source": [
    "### Below the filter name: ANY(..) matches ensure the query is against only the documents' metadata satisfying that criteria."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a60f0bee-f05c-44af-b101-7ee17f403d76",
   "metadata": {},
   "outputs": [],
   "source": [
    "%%bash\n",
    "curl -X POST -H \"Authorization: Bearer $(gcloud auth print-access-token)\" \\\n",
    "-H \"Content-Type: application/json\" \\\n",
    "\"https://discoveryengine.googleapis.com/v1beta/projects/<PROJECT>/locations/global/collections/default_collection/dataStores/<ES_STORE_ID>/servingConfigs/default_search:search\" \\\n",
    "-d '{\n",
    "\"servingConfig\": \"projects/<PROJECT>/locations/global/collections/default_collection/dataStores/<ES_STORE_ID>/servingConfigs/default_search\",\n",
    "\"query\": \"claims\",\n",
    "\"filter\": \"category: ANY(\\\"PersonaB\\\")\"\n",
    "}'"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "587b3406-7904-492d-a496-41f60218457c",
   "metadata": {},
   "source": [
    "### Python Code equivalent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cd018610-0612-48d0-a6da-cf32d0f9f4bf",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Local import of retriever class\n",
    "import sys, os\n",
    "#sys.path.append(os.path.abspath(\"..\"))\n",
    "from utils.es import es_raw_search_summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "518acf70-3057-4c05-be9a-edb0c548d661",
   "metadata": {},
   "outputs": [],
   "source": [
    "PROJECT_ID = \"providersearch-378121\"\n",
    "SEARCH_ENGINE_ID = \"bms-eln-07202023_1689884137276\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cd59d6af-623c-4901-8545-483a89c9b7f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "query = \"how to process a claim\"\n",
    "rawresults = None\n",
    "summary, rawresults = es_raw_search_summary(PROJECT_ID, SEARCH_ENGINE_ID, query, filtername=\"name: ANY(\\\"Document1\\\")\")\n",
    "print(f\"\\nQuestion: '{query}'\\n\\nES Summary: '{summary}'\")\n",
    "print(\"Rawresult\" + \"-\"*40)\n",
    "print(rawresults)\n",
    "print(\"Summary\" + \"-\"*40)\n",
    "print(summary)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8318a8f2-ffed-4b7e-b280-4e2f2707162f",
   "metadata": {},
   "source": [
    "## In this example I set a slightly more complex filter based on 2 metadata values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5cd4a768-4747-48cf-aec4-04d87f5cc736",
   "metadata": {},
   "outputs": [],
   "source": [
    "query = \"how to process a claim\"\n",
    "rawresults = None\n",
    "filtersample = \"name: ANY(\\\"Document1\\\") AND category: ANY(\\\"PersonaA\\\")\"\n",
    "summary, rawresults = es_raw_search_summary(PROJECT_ID, SEARCH_ENGINE_ID, query, filtername=filtersample)\n",
    "print(f\"\\nQuestion: '{query}'\\n\\nES Summary: '{summary}'\")\n",
    "prin t(\"Rawresult\" + \"-\"*40)\n",
    "print(rawresults)\n",
    "print(\"Summary\" + \"-\"*40)\n",
    "print(summary)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7355305e-989c-4c71-aabe-794cceb9d0a5",
   "metadata": {},
   "source": [
    "## Create a Control ID for Synonymns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "22170934-25fe-4541-85fa-04f255fd1675",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n",
      "                                 Dload  Upload   Total   Spent    Left  Speed\n",
      "100   543    0   364  100   179    329    162  0:00:01  0:00:01 --:--:--   491\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/controls/test2\",\n",
      "  \"displayName\": \"test2\",\n",
      "  \"solutionType\": \"SOLUTION_TYPE_SEARCH\",\n",
      "  \"useCases\": [\n",
      "    \"SEARCH_USE_CASE_SEARCH\"\n",
      "  ],\n",
      "  \"synonymsAction\": {\n",
      "    \"synonyms\": [\n",
      "      \"camzyos\",\n",
      "      \"yabagaba345\",\n",
      "      \"tororoavds245\"\n",
      "    ]\n",
      "  }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "%%bash\n",
    "\n",
    "curl -X POST \\\n",
    "-H \"Authorization: Bearer $(gcloud auth application-default print-access-token)\" \\\n",
    "-H \"Content-Type: application/json; charset=utf-8\" \\\n",
    "-H \"X-Goog-User-Project: 9057658179\" --data \\\n",
    "'{\"displayName\": \"test2\",\"solutionType\": \"SOLUTION_TYPE_SEARCH\", \"useCases\": [\"SEARCH_USE_CASE_SEARCH\"], \"synonymsAction\": {\"synonyms\" : [\"camzyos\",\"yabagaba345\",\"tororoavds245\"]}}' \"https://discoveryengine.googleapis.com/v1alpha/projects/9057658179/locations/global/dataStores/bsm-therap_1695917255391/controls?controlId=test2\""
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bdc21b09-2dd3-4a49-ac90-80b46788cb7d",
   "metadata": {},
   "source": [
    "## Update the serving config with the above Control ID "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "7917f8d9-a8ae-4267-8de8-97d8d0d9080e",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n",
      "                                 Dload  Upload   Total   Spent    Left  Speed\n",
      "100   303    0   270  100    33    647     79 --:--:-- --:--:-- --:--:--   726\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/servingConfigs/default_search\",\n",
      "  \"displayName\": \"default_search\",\n",
      "  \"solutionType\": \"SOLUTION_TYPE_SEARCH\",\n",
      "  \"synonymsControlIds\": [\n",
      "    \"test2\"\n",
      "  ]\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "%%bash\n",
    "curl -X PATCH -H \"Authorization: Bearer $(gcloud auth print-access-token)\" \\\n",
    "-H \"Content-Type: application/json\" \\\n",
    "-H \"X-Goog-User-Project: 9057658179\" \\\n",
    "\"https://discoveryengine.googleapis.com/v1alpha/projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/servingConfigs/default_search?update_mask=synonyms_control_ids\" \\\n",
    "-d '{\"synonymsControlIds\": [\"test2\"]}'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "05bf75ef-8f90-4d42-95b6-8c9c3ce846b6",
   "metadata": {},
   "outputs": [],
   "source": [
    "## Issue a query with the updated servingConfig"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "d10cdac6-c390-4081-8fa5-8c847cd37a01",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n",
      "                                 Dload  Upload   Total   Spent    Left  Speed\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"results\": [\n",
      "    {\n",
      "      \"id\": \"92948d62a9d36e93474bbf860df9e174\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/92948d62a9d36e93474bbf860df9e174\",\n",
      "        \"id\": \"92948d62a9d36e93474bbf860df9e174\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"10 6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: • cardiac conduction abnormalities [see Warnings and Precautions (5.1)] • rash [see Warnings and Precautions (5.2)] • effects on serum creatinine [see Warnings and Precautions (5.3)] • new onset or worsening renal impairment when used with tenofovir DF [see Warnings and Precautions (5.4)] • chronic kidney disease [see Warnings and Precautions (5.5)] • nephrolithiasis and cholelithiasis [see Warnings and Precautions (5.6)] • hepatotoxicity [see Warnings and Precautions (5.7)] • hyperbilirubinemia [see Warnings and Precautions (5.10)] For additional safety information about atazanavir and cobicistat, consult the full prescribing information for these individual products.\",\n",
      "              \"pageNumber\": \"10\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_evotaz.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"049545fd8a45ff6fe23e8484ac167cca\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/049545fd8a45ff6fe23e8484ac167cca\",\n",
      "        \"id\": \"049545fd8a45ff6fe23e8484ac167cca\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_camzyos.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"2\",\n",
      "              \"content\": \"FULL PRESCRIBING INFORMATION WARNING: RISK OF HEART FAILURE CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction [see Warnings and Precautions (5.1)]. Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS.\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"04bffcf1db60b2a1e4d30e5de08106db\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/04bffcf1db60b2a1e4d30e5de08106db\",\n",
      "        \"id\": \"04bffcf1db60b2a1e4d30e5de08106db\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"Psychiatric Symptoms Inform patients that serious psychiatric symptoms including severe depression, suicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms and catatonia have been reported in patients receiving SUSTIVA [see Warnings and Precautions (5.5)].\",\n",
      "              \"pageNumber\": \"37\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_sustiva.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"bf3a715c0cf4ad37b1974d861ca215b4\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/bf3a715c0cf4ad37b1974d861ca215b4\",\n",
      "        \"id\": \"bf3a715c0cf4ad37b1974d861ca215b4\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_thalomid.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"4\",\n",
      "              \"content\": \"Monitor blood counts, including platelet counts. Dose reduction, delay, or discontinuation may be required. Monitor for signs and symptoms of bleeding including petechiae, epistaxis, and gastrointestinal bleeding, especially if concomitant medication may increase the risk of bleeding.\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"98b4c1b42a3efbcbfdce514a20438ba0\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/98b4c1b42a3efbcbfdce514a20438ba0\",\n",
      "        \"id\": \"98b4c1b42a3efbcbfdce514a20438ba0\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_revlimid.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"24\",\n",
      "              \"content\": \"Venous and Arterial Thromboembolism Inform patients of the risk of thrombosis including DVT, PE, MI, and stroke and to report immediately any signs and symptoms suggestive of these events for evaluation [see Boxed Warning and Warnings and Precautions (5.4)].\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"9a0409577ffa8de716e9c8284db57931\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/9a0409577ffa8de716e9c8284db57931\",\n",
      "        \"id\": \"9a0409577ffa8de716e9c8284db57931\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_pomalyst.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"12\",\n",
      "              \"content\": \"Dizziness and Confusional State Inform patients of the potential risk of dizziness and confusional state with the drug, to avoid situations where dizziness or confusional state may be a problem, and not to take other medications that may cause dizziness or confusional state without adequate medical advice [see Warnings and Precautions (5.8)].\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"19b47a8465c1cdbf24a26d3db0b90547\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/19b47a8465c1cdbf24a26d3db0b90547\",\n",
      "        \"id\": \"19b47a8465c1cdbf24a26d3db0b90547\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"2\",\n",
      "              \"content\": \"ZEPOSIA may therefore increase the susceptibility to infections, some serious in nature. Life-threatening and rare fatal infections have occurred in patients receiving ZEPOSIA.\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_zeposia.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"a1aa0d32d70e5b4cac82c3cade70719a\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/a1aa0d32d70e5b4cac82c3cade70719a\",\n",
      "        \"id\": \"a1aa0d32d70e5b4cac82c3cade70719a\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_inrebic.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"INREBIC® (fedratinib) INREBIC® (fedratinib) not indicated. Advise patients, especially current or past smokers or patients with other cardiovascular risk factors, to be alert for the development of signs and symptoms of cardiovascular events [see Warnings and Precautions (5.6)].\",\n",
      "              \"pageNumber\": \"8\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"8e08402d86fe391def911e0582344d67\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/8e08402d86fe391def911e0582344d67\",\n",
      "        \"id\": \"8e08402d86fe391def911e0582344d67\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"The most common nonlaboratory adverse reactions (≥20%) were fever, CRS, musculoskeletal pain, headache, fatigue, nausea, constipation, and dizziness.\",\n",
      "              \"pageNumber\": \"6\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_breyanzi.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"12546c3d986085f9cf7e009787fe73f7\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/12546c3d986085f9cf7e009787fe73f7\",\n",
      "        \"id\": \"12546c3d986085f9cf7e009787fe73f7\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_sprycel.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"Advise patients to seek immediate medical attention if any symptoms suggestive of hepatotoxicity occur, such as \\u003cb\\u003eabdominal pain, jaundice and scleral icterus, anorexia, bleeding, bruising, and dark-colored urine\\u003c/b\\u003e [see Warnings and Precautions (5.11)].\",\n",
      "              \"pageNumber\": \"12\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"975531ecc1790b0cb898d257e5469bb4\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/975531ecc1790b0cb898d257e5469bb4\",\n",
      "        \"id\": \"975531ecc1790b0cb898d257e5469bb4\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"The most common adverse reactions (reported in ≥20% of patients and at a higher incidence than in the dacarbazine arm) were fatigue, musculoskeletal pain, rash, and pruritus. Tables 7 and 8 summarize selected adverse reactions and laboratory abnormalities, respectively, in CHECKMATE-066. (Continued)\",\n",
      "              \"pageNumber\": \"10\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_opdivo.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"4a2359a7205d8e1703b0d69092205f36\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/4a2359a7205d8e1703b0d69092205f36\",\n",
      "        \"id\": \"4a2359a7205d8e1703b0d69092205f36\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_reyataz.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"12\",\n",
      "              \"content\": \"6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: • cardiac conduction abnormalities [see Warnings and Precautions (5.1)] • rash [see Warnings and Precautions (5.2)] • hyperbilirubinemia [see Warnings and Precautions (5.8)] • chronic kidney disease [see Warnings and Precautions (5.5)] • nephrolithiasis and cholelithiasis [see Warnings and Precautions (5.6)] 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"c41211dcf7bba3ae6c4e3d3847410e85\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/c41211dcf7bba3ae6c4e3d3847410e85\",\n",
      "        \"id\": \"c41211dcf7bba3ae6c4e3d3847410e85\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_opdualag.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"• Hepatitis: Advise patients to contact their healthcare provider immediately for jaundice, severe nausea or vomiting, pain on the right side of abdomen, lethargy, or easy bruising or bleeding [see Warnings and Precautions (5.1)].\",\n",
      "              \"pageNumber\": \"7\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"1e035cd0cd3e671bcf455767026fb71f\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/1e035cd0cd3e671bcf455767026fb71f\",\n",
      "        \"id\": \"1e035cd0cd3e671bcf455767026fb71f\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"11\",\n",
      "              \"content\": \"Severe Myelosuppression • Patients must be informed of the risk of low blood cell counts and severe and life threatening infections and instructed to contact their healthcare provider immediately for fever or evidence of infection [see Warnings and Precautions (5.1), (5.3)].\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_abraxane.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"c422b3c05572225b932366e82ac3dfcc\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/c422b3c05572225b932366e82ac3dfcc\",\n",
      "        \"id\": \"c422b3c05572225b932366e82ac3dfcc\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_orencia.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"The most serious adverse reactions were serious infections and malignancies. The most commonly reported adverse events (occurring in ≥10% of patients treated with ORENCIA) were headache, upper respiratory tract infection, nasopharyngitis, and nausea.\",\n",
      "              \"pageNumber\": \"4\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"7725c2d303ee142b32649e4efe82cf33\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/7725c2d303ee142b32649e4efe82cf33\",\n",
      "        \"id\": \"7725c2d303ee142b32649e4efe82cf33\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_abecma.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"Advise patients to seek immediate attention for any of the following: • Cytokine Release Syndrome (CRS): Signs or symptoms associated with CRS, including fever, hypotension, tachycardia, chills, hypoxia, headache, and fatigue [see Dosage and Administration (2.3), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].\",\n",
      "              \"pageNumber\": \"9\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"34774dbcf73415e0d1d8e438e72148ce\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/34774dbcf73415e0d1d8e438e72148ce\",\n",
      "        \"id\": \"34774dbcf73415e0d1d8e438e72148ce\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"9\",\n",
      "              \"content\": \"Pregnancy • Advise patients that lenalidomide and pomalidomide have the potential to cause fetal harm and has specific requirements regarding contraception, pregnancy testing, blood and sperm donation, and transmission in sperm.\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_empliciti.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"ffe306b3f0427a447f77bd6508639f63\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/ffe306b3f0427a447f77bd6508639f63\",\n",
      "        \"id\": \"ffe306b3f0427a447f77bd6508639f63\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"The most common serious infections reported with SOTYKTU included pneumonia and COVID-19 [see Adverse Reactions (6.1)]. Avoid use of SOTYKTU in patients with an active or serious infection.\",\n",
      "              \"pageNumber\": \"2\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_sotyktu.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"2f1e67257734af42ab4b05fd44737a23\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/2f1e67257734af42ab4b05fd44737a23\",\n",
      "        \"id\": \"2f1e67257734af42ab4b05fd44737a23\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"3\",\n",
      "              \"content\": \"5.5 Other Serious Infections Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_nulojix.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"d49f54263fa4da78789fb7a3c7367701\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/d49f54263fa4da78789fb7a3c7367701\",\n",
      "        \"id\": \"d49f54263fa4da78789fb7a3c7367701\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_istodax.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"6\",\n",
      "              \"content\": \"Advise patients to report fever, cough, shortness of breath with or without chest pain, burning on urination, flu-like symptoms, muscle aches, or worsening skin problems. Advise patients to report any previous history of hepatitis B before starting romidepsin [see Warnings and Precautions (5.2)].\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"af9f00f68be534946dc26cc2702f2122\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/af9f00f68be534946dc26cc2702f2122\",\n",
      "        \"id\": \"af9f00f68be534946dc26cc2702f2122\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"7\",\n",
      "              \"content\": \"The most frequent (≥10%) serious adverse reactions in the YERVOY and nivolumab arm were diarrhea (13%), colitis (10%), and pyrexia (10%).\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_yervoy.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"85ca3d26de62838f90490a3ea0051134\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/85ca3d26de62838f90490a3ea0051134\",\n",
      "        \"id\": \"85ca3d26de62838f90490a3ea0051134\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"2.7 Use in Geriatric Patients Azacitidine and its metabolites are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.\",\n",
      "              \"pageNumber\": \"2\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_vidaza.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"eff2e00462b40e2faa2215513cce9e4a\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/eff2e00462b40e2faa2215513cce9e4a\",\n",
      "        \"id\": \"eff2e00462b40e2faa2215513cce9e4a\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"Effects on Blood Pressure Caution patients that REBLOZYL may cause an increase in blood pressure [see Warnings and Precautions (5.2)]. Extramedullary Hematopoietic Masses Advise patients with beta thalassemia of the potential risk of extramedullary hematopoietic masses.\",\n",
      "              \"pageNumber\": \"8\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_reblozyl.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"c931e1ec53deb43fe7fcc57293eb4315\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/c931e1ec53deb43fe7fcc57293eb4315\",\n",
      "        \"id\": \"c931e1ec53deb43fe7fcc57293eb4315\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"1\",\n",
      "              \"content\": \"Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution (5.1, 6.1).\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_idhifa.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"57f8b311cf5149288a32cdbdb3892acc\",\n",
      "      \"document\": {\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100 24276    0 24069  100   207  49524    425 --:--:-- --:--:-- --:--:-- 49950\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/57f8b311cf5149288a32cdbdb3892acc\",\n",
      "        \"id\": \"57f8b311cf5149288a32cdbdb3892acc\",\n",
      "        \"derivedStructData\": {\n",
      "          \"link\": \"gs://rk_bms_therap/pi_onureg.pdf\",\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"6\",\n",
      "              \"content\": \"Gastrointestinal Toxicity Advise patients of the risk of gastrointestinal toxicity with ONUREG and of the potential need to use anti-emetic or anti-diarrheal medications during treatment [see Adverse Reactions (6.1)].\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"5d0ae82e92294f96c603bb7396fd1618\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/5d0ae82e92294f96c603bb7396fd1618\",\n",
      "        \"id\": \"5d0ae82e92294f96c603bb7396fd1618\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"content\": \"FULL PRESCRIBING INFORMATION: CONTENTS * WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS CO-INFECTED WITH HIV AND HBV, AND LACTIC ACIDOSIS AND HEPATOMEGALY 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Timing of Administration 2.2 Recommended Dosage in Adults 2.3 Recommended Dosage in Pediatric Patients 2.4 Renal Impairment 2.5 Hepatic Impairment 2.6 Duration of Therapy 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Severe Acute Exacerbations of Hepatitis B 5.2 Patients Co-infected with HIV and HBV 5.3 Lactic Acidosis and Severe Hepatomegaly with Steatosis 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Racial/Ethnic Groups 8.7 Renal Impairment 8.8 Liver Transplant Recipients 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.3 Pharmacokinetics 12.4 Microbiology 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Outcomes in Adults 14.2 Outcomes in Pediatric Subjects 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed.\",\n",
      "              \"pageNumber\": \"1\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_baraclude.pdf\"\n",
      "        }\n",
      "      }\n",
      "    },\n",
      "    {\n",
      "      \"id\": \"a6d709781cb2f587d50d51912f0a5425\",\n",
      "      \"document\": {\n",
      "        \"name\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/branches/0/documents/a6d709781cb2f587d50d51912f0a5425\",\n",
      "        \"id\": \"a6d709781cb2f587d50d51912f0a5425\",\n",
      "        \"derivedStructData\": {\n",
      "          \"extractive_answers\": [\n",
      "            {\n",
      "              \"pageNumber\": \"2\",\n",
      "              \"content\": \"ELIQUIS® FULL PRESCRIBING INFORMATION (apixaban) WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.\"\n",
      "            }\n",
      "          ],\n",
      "          \"link\": \"gs://rk_bms_therap/pi_eliquis.pdf\"\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  ],\n",
      "  \"totalSize\": 1610,\n",
      "  \"attributionToken\": \"W_BaCgwIte7YqAYQxIaRsAMSJDY1MTVhMzhiLTAwMDAtMjUzYi05MDExLTE0YzE0ZWVmNDRkOCIHR0VORVJJQyocjr6dFaaL7xebho4in4aOItSynRXC8J4VxcvzFw\",\n",
      "  \"guidedSearchResult\": {},\n",
      "  \"summary\": {}\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "%%bash\n",
    "curl -X POST -H \"Authorization: Bearer $(gcloud auth print-access-token)\" \\\n",
    "-H \"Content-Type: application/json\" \\\n",
    "\"https://discoveryengine.googleapis.com/v1beta/projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/servingConfigs/default_search:search\" \\\n",
    "-d '{\n",
    "\"servingConfig\": \"projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/servingConfigs/default_search\",\n",
    "\"query\": \"What are the warnings for yabagaba345\",\n",
    "}'\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cab601dc-aaa9-4229-8423-44bcad8d40e6",
   "metadata": {},
   "outputs": [],
   "source": [
    "%%bash\n",
    "curl -X PATCH -H \"Authorization: Bearer $(gcloud auth print-access-token)\" \\\n",
    "-H \"Content-Type: application/json\" \\\n",
    "-H \"X-Goog-User-Project: 9057658179\" \\\n",
    "-d '{\"synonymsControlIds\": [\"test1\"]}' \\\n",
    "\"https://discoveryengine.googleapis.com/v1alpha/projects/9057658179/locations/global/collections/default_collection/dataStores/bsm-therap_1695917255391/servingConfigs/default_search\" "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "acc142c1-43ca-4cf3-8386-a9526082f08a",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "31ac07b0-a008-4b99-ab23-90060be4ccc5",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "environment": {
   "kernel": "python3",
   "name": "common-cpu.m108",
   "type": "gcloud",
   "uri": "gcr.io/deeplearning-platform-release/base-cpu:m108"
  },
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
